epinastine (elestat) Report issue

Small molecule Approved FDA
AACT ChEMBL DrugBank Drug Central Drugs@FDA KEGG MeSH PubChem repoDB

Active Ingredient History

NOW
  • Now
Epinastine (brand names Alesion, Elestat, Purivist, Relestat) is a second-generation antihistamine and mast cell stabilizer. Epinastine is a topically active, direct H1-receptor antagonist and an inhibitor of the release of histamine from the mast cell. Epinastine is selective for the histamine H1-receptor and has affinity for the histamine H2 receptor. Epinastine also possesses affinity for the α1-, α2-, and 5-HT2 –receptors. Epinastine does not penetrate the blood/brain barrier and, therefore, is not expected to induce side effects of the central nervous system. Elestat ophthalmic solution is indicated for the prevention of itching associated with allergic conjunctivitis.   NCATS

Chemistry

More Chemistry

Pharmacology

  • Mechanism of Action:
  • Multi-specific: Missing data
  • Black Box: No
  • Availability: Prescription Only
  • Delivery Methods: Topical
  • Pro Drug: No

Drug Pricing (per unit)

United States

$6.8876 - $13.7240
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

Alternative names

3-amino-9,13b-dihydro-1h-benz(c,f)imidazo(1,5a)azepine | 3-amino-9,13b-dihydro-1h-dibenz(c,f)imidazo(1,5-a)azepine | alesion | de-114 | elestat | epinastin | epinastina | epinastine | (+-)-epinastine | (+/-)-epinastine | epinastine hcl | epinastine hydrochloride | epinastinum | flurinol | relestat | wal 80 | wal 801 | wal801cl | wal 801cl | wal 801 cl | wal-80 cl

Organizations (21)

Research & Development (8)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (13)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (7)

Approved Indications (1)


 

Conjunctivitis, Allergic

Experimental Indications - Clinical Trial Phases 1-4 (7)


 

Conjunctivitis, Allergic (Phase 4)

Dermatitis, Atopic (Phase 3)

Healthy Volunteers (Phase 1)

Hypersensitivity (Phase 4)

Rhinitis, Allergic (Phase 2)

Rhinitis, Allergic, Perennial (Phase 3)

Rhinitis, Allergic, Seasonal (Phase 3)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 16
  • # of Trial Organizations: 8

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue